Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Swedish Pharmalink receives Orphan Drug Approval for Busulipo

Authored by James Sheppard The Swedish speciality pharmaceutical company Pharmalink AB announced that it had received Orphan Drug approval from the US FDA for oncology conditioning agent Busulipo. Busulipo is indicated for use in cancer patients prior to hematopoietic stem … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

NPS Pharma submits BLA for Natpara

Authored by James Sheppard US rare disease specialist NPS Pharmaceuticals announced that it has submitted a Biologic License Application (BLA) to the US FDA for Natpara. The product is a bioengineered replacement for endogenous parathyroid hormone (PTH) which is indicated … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

Osiris sells stem cell business in $100m deal

Authored by James Sheppard The US based biotechnology company Osiris Therapeutics has announced a $100m deal with Australian biotech Mesoblast for the company to buy its stem cell platform. The deal includes Osiris’s off the shelf stem cell product Prochymal. … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

immatics bags $46m for Phase III cancer vaccine

Authored by James Sheppard The German biotech company immatics, backed by biotech billionaire Dietmar Hopp, has secured a further $46m in series D funding for its cancer vaccine IMA901. The funding was provided by Hopp Biotech, Wellington Partners, MIG-advised funds … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

AstraZeneca makes play in ADC market

Authored by James Sheppard Global pharmaceutical giant AstraZeneca has recently announced the acquisition of UK based antibody-drug conjugate (ADC) specialist Spirogen. The deal will put Spirogen as part of AstraZeneca’s biologics unit, MedImmune. The deal is worth an estimated $440m … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Pfizer gains experimental drug from Gliknik

Authored by James Sheppard Global pharmaceutical giant Pfizer has signed a deal with tiny US biotech Gliknik for the experimental drug GL-2045. GL-2045 is being developed for the treatment of autoimmune diseases and cancer. As part of the deal, Gliknik … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

Pacific Biosciences rockets after Roche Deal

Authored by James Sheppard Global pharma and diagnostics giant Roche and US based Pacific Biosciences (PacBio) have signed a $75m product development deal. The deal will see PacBio develop and make gene sequencing and other clinical products and license them … Continue reading

Posted in Medical Device, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap